Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 42291-634

9 FDA label images from Avkare · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 42291-634). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label 10mg 100ct 2018 05 23

Label 10mg 100ct 2018 05 23
Oxybutynin Chloride Extended Release Tablets USP 10 mg by AvKARE, shown on a partial label featuring the product name, strength, and tablet count of 100. The label includes directions, storage information, manufacturer address, and an NDC barcode.*
FDA Label Image

Label 15mg 100ct 2018 05 21

Label 15mg 100ct 2018 05 21
Oxybutynin Chloride Extended Release Tablets USP 15 mg in a package labeled by AvKARE. The label indicates 100 tablets, Rx only, with storage instructions and manufacturing details. The dosage strength of 15 mg is highlighted on the label.*
FDA Label Image

Label 5mg 500ct 2018 05 21

Label 5mg 500ct 2018 05 21
Label for Oxybutynin Chloride Extended Release Tablets USP 5 mg by AvKARE. The label indicates a bottle containing 500 tablets, prescription only. It shows storage and usage instructions, barcode, and manufacturer information on the side panel.*
FDA Label Image

Chemical Structure (Oxybutynin 1)

Chemical Structure (Oxybutynin 1)
Chemical structure diagram of oxybutynin chloride, showing its molecular components and arrangement including the hydrochloride group.*
FDA Label Image

Figure 1 (Oxybutynin 2)

Figure 1 (Oxybutynin 2)
A line chart comparing the mean plasma oxybutynin concentration (ng/mL) over 24 hours between oxybutynin chloride extended-release tablets and oxybutynin 5 mg taken three times daily (TID). The x-axis represents time in hours, and the y-axis shows plasma concentration, with error bars indicating variability at each time point.*
FDA Label Image

Figure 2 (Oxybutynin 3)

Figure 2 (Oxybutynin 3)
A line graph showing mean R-Oxybutynin plasma concentration (ng/mL) over time (hours), with data points at 0, 4, 6, 8, and 24 hours. The graph depicts a slight initial increase in concentration followed by a gradual decrease, including error bars around each data point.*
FDA Label Image

Figure 2 (Oxybutynin 4)

Figure 2 (Oxybutynin 4)
A horizontal bar chart comparing the mean change in episodes per week from baseline for Oxybutynin chloride extended-release tablets versus placebo. The chart displays mean changes with standard deviation error bars on a scale from -40 to 40 episodes.*
FDA Label Image

Figure 3 (Oxybutynin 5)

Figure 3 (Oxybutynin 5)
A horizontal bar chart displaying mean changes with standard deviation in episodes per week from baseline for oxybutynin chloride extended-release tablets. The x-axis measures change in episodes per week ranging from -40 to 40, with a data point indicated near -20 for oxybutynin.*
FDA Label Image

Figure 4 (Oxybutynin 6)

Figure 4 (Oxybutynin 6)
A line graph depicting the mean change with standard deviation in episodes per week from baseline for oxybutynin chloride extended-release tablets compared to oxybutynin, with the horizontal axis showing values from -40 to 40.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.